MNOV
MediciNova, Inc. NASDAQ Listed Dec 8, 2006$1.31
Mkt Cap $64.5M
52w Low $1.17
17.7% of range
52w High $1.96
50d MA $1.37
200d MA $1.41
P/E (TTM)
—
EV/EBITDA
—
P/B
1.6x
Debt/Equity
0.0x
ROE
-28.8%
P/FCF
-6.7x
RSI (14)
48.60
ATR (14)
$0.05
Beta
0.61
50d MA
$1.37
200d MA
$1.41
Avg Volume
42.7K
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
4275 Executive Square · La Jolla, CA 92037 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | BMO | -0.06 | -0.05 | +16.7% | 1.40 | -2.1% | -1.4% | +0.7% | -0.7% | +0.7% | -1.4% | — |
| May 13, 2026 | BMO | — | — | — | 1.38 | +0.0% | -0.7% | +2.2% | -1.4% | +0.7% | -0.7% | — |
| Feb 20, 2026 | BMO | -0.10 | -0.05 | +47.4% | 1.50 | -2.0% | -0.7% | -9.4% | +9.6% | +2.7% | -4.6% | — |
| Nov 12, 2025 | BMO | -0.08 | -0.06 | +25.0% | 1.57 | -2.5% | -1.9% | +0.6% | -9.0% | +2.1% | -0.7% | — |
| Aug 14, 2025 | BMO | -0.07 | -0.07 | +0.0% | 1.30 | -1.5% | +0.8% | +0.0% | -0.8% | +0.8% | -1.5% | — |
| May 13, 2025 | BMO | -0.14 | -0.06 | +57.1% | 1.46 | +3.4% | -6.2% | +1.5% | -5.0% | +6.1% | -2.1% | — |
| Feb 19, 2025 | BMO | -0.06 | -0.06 | +0.0% | 1.97 | -4.1% | -9.6% | +2.8% | -3.8% | -1.1% | -4.6% | — |
| Nov 13, 2024 | BMO | -0.06 | -0.06 | +0.0% | 2.00 | +4.5% | -8.5% | +0.0% | -1.6% | +5.6% | +2.6% | — |
| Aug 8, 2024 | BMO | -0.06 | -0.05 | +16.7% | 1.15 | +0.9% | +0.9% | -2.6% | +0.0% | +0.9% | +1.8% | — |
| May 9, 2024 | BMO | -0.05 | -0.06 | -20.0% | 1.46 | +1.4% | +4.8% | -0.7% | -2.6% | +0.7% | -4.0% | — |
| Feb 15, 2024 | BMO | -0.08 | -0.04 | +50.0% | 1.35 | +0.7% | +0.7% | +0.7% | -1.5% | -1.5% | -3.8% | — |
| Nov 9, 2023 | BMO | -0.08 | -0.01 | +87.5% | 1.79 | +2.5% | -0.6% | +0.8% | -3.1% | +1.1% | +0.0% | — |
| Aug 9, 2023 | BMO | -0.07 | -0.06 | +14.3% | 2.36 | +0.8% | +1.7% | +0.2% | -1.0% | -2.9% | +6.9% | — |
| May 11, 2023 | BMO | -0.07 | -0.06 | +14.3% | 2.16 | +3.7% | +0.0% | +2.1% | -0.7% | +0.9% | -4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30 | D. Boral Capital | Maintains | Buy → Buy | — | $1.75 | $1.83 | +4.6% | -1.7% | -3.5% | -1.2% | -0.6% | -0.6% |
| Dec 18 | D. Boral Capital | Maintains | Buy → Buy | — | $1.47 | $1.49 | +1.4% | -1.4% | -1.4% | -2.8% | -5.0% | -3.0% |
| Dec 8 | D. Boral Capital | Maintains | Buy → Buy | — | $1.56 | $1.58 | +1.3% | -3.2% | +2.0% | -1.9% | +0.0% | +2.0% |
| Nov 4 | D. Boral Capital | Maintains | Buy → Buy | — | $1.50 | $1.43 | -4.7% | -5.3% | +6.3% | -7.3% | +1.4% | -0.7% |
| Oct 31 | D. Boral Capital | Maintains | Buy → Buy | — | $1.19 | $1.36 | +14.3% | +39.5% | -9.6% | -5.3% | +6.3% | -7.3% |
| Sep 22 | D. Boral Capital | Maintains | Buy → Buy | — | $1.27 | $1.29 | +1.6% | +0.8% | -0.8% | -1.6% | -0.8% | +2.4% |
| Aug 27 | D. Boral Capital | Maintains | Buy → Buy | — | $1.36 | $1.43 | +5.1% | -1.5% | +0.0% | -2.2% | +0.0% | +0.8% |
| Jul 24 | D. Boral Capital | Maintains | Buy → Buy | — | $1.26 | $1.25 | -0.8% | -1.6% | +17.7% | -0.7% | -8.3% | +1.5% |
| Jun 16 | B. Riley Securities | Maintains | Buy → Buy | — | $1.33 | $1.32 | -0.8% | +0.0% | -5.3% | +0.8% | +1.6% | +1.6% |
| Apr 9 | D. Boral Capital | Maintains | Buy → Buy | — | $1.24 | $1.26 | +1.6% | +5.6% | -3.1% | +8.7% | +1.4% | +0.0% |
| Mar 14 | D. Boral Capital | Maintains | Buy → Buy | — | $1.47 | $1.51 | +2.7% | +5.4% | -0.6% | -2.6% | +3.3% | -2.6% |
| Feb 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.78 | $1.80 | +1.1% | +2.8% | -3.8% | -1.1% | -4.6% | +1.2% |
| Dec 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.26 | $2.33 | +3.1% | +3.5% | -1.7% | -1.7% | -4.0% | -1.4% |
| Mar 13 | B. Riley FBR | Maintains | Buy → Buy | — | $3.13 | $3.47 | +10.9% | +28.8% | -2.5% | +5.6% | -21.0% | +5.2% |
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $3.13 | $3.47 | +10.9% | +28.8% | -2.5% | +5.6% | -21.0% | +5.2% |
| May 24 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $2.75 | $1.29 | -53.1% | -42.9% | +11.5% | -0.4% | -0.7% | +1.2% |
No insider trades available.
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Essex Woodlands Management, Inc. | 1,105,941 | $2M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 611,039 | $837K | New | Mar 2026 |
| 3 | Citigroup Inc | 635,715 | $833K | Added | Dec 2025 |
| 4 | Ubs Group Ag | 222,200 | $304K | Reduced | Mar 2026 |
| 5 | Renaissance Technologies Llc | 189,900 | $260K | Reduced | Mar 2026 |
| 6 | Barclays Plc | 162,900 | $223K | Added | Mar 2026 |
| 7 | Jane Street Group, Llc | 163,096 | $214K | New | Dec 2025 |
| 8 | Northern Trust Corp | 133,163 | $182K | — | Mar 2026 |
| 9 | Bank Of New York Mellon Corp | 78,277 | $107K | Reduced | Mar 2026 |
| 10 | Susquehanna International Group, Llp | 43,926 | $60K | Added | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 34,359 | $47K | Reduced | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 29,809 | $41K | Reduced | Mar 2026 |
| 13 | Jpmorgan Chase & Co | 20,576 | $28K | Added | Mar 2026 |
| 14 | Morgan Stanley | 4,000 | $5K | — | Dec 2025 |
| 15 | Northwestern Mutual Wealth Management Co | 305 | $400 | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 10
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 255,652 | $371K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 115,072 | $158K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 87,575 | $127K | Feb 2026 |
| 4 | Schwab Total Stock Market Index Fund | 71,506 | $123K | Jan 2026 |
| 5 | Fidelity Series Total Market Index Fund | 65,908 | $96K | Feb 2026 |
| 6 | Ultra-Small Company Market Fund | 50,247 | $69K | Mar 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 25,966 | $38K | Feb 2026 |
| 8 | Small Cap Core Fund | 13,894 | $19K | Mar 2026 |
| 9 | LVIP Dimensional U.S. Core Equity 2 Fund | 6,693 | $9K | Mar 2026 |
| 10 | AST Small-Cap Equity Portfolio | 4,930 | $6K | Dec 2025 |
Valuation
Market Cap
$64.5M
Enterprise Value
$34.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-1.23x
P/B
1.55x
P/S
108.07x
P/FCF
-6.65x
EV/EBITDA
—
Shares Out
49.1M
Financials (TTM)
Revenue
$597K
Net Income
-$11.7M
EBITDA
-$11.7M
Free Cash Flow
-$9.8M
Op Cash Flow
-$9.8M
EPS Basic
$-0.24
EPS Diluted
$-0.23
EPS Forward
$-0.30
Gross Margin
15.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$45.6M
Total Liab.
$4.0M
Total Equity
$41.6M
Cash
$30.8M
LT Debt
$0
Book Value/Sh
$0.85
Debt/Equity
0.00x
Current Ratio
8.16
Quick Ratio
8.16
Returns & Growth
ROE
-28.8%
ROA
-26.3%
ROIC
-31.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-4.3%
Price Returns
2W
-2.9%
1M
-2.2%
3M
-6.2%
6M
-6.2%
12M
-2.2%
Technicals
52W High
$1.96
52W Low
$1.17
50d MA
$1.37
200d MA
$1.41
RSI (14)
48.60
ATR (14)
$0.05
Beta
0.61
Avg Volume
43K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 12:47pm
· Source: financialmodelingprep.com